Blueskeye AI

Blueskeye uses machine learning to analyse social, emotional and medically relevant expressed behaviour, delivering objective, real-time insights with greater accuracy than human observation.

Co-founded in 2019 as a spin-out from the University of Nottingham’s School of Computer Science by Professor Michel Valstar, the company has commercialised more than 22 years of research into expressed emotion. Its clinical-grade technology has been rigorously tested to demonstrate both efficacy and safety.

In a major regulatory milestone, Blueskeye’s TrueBlue app has been accepted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a registered Class I medical device, marking the first regulatory recognition for the company’s face and voice behaviour analysis technology in perinatal mental health.

Using only a smartphone’s camera and microphone, TrueBlue detects digital biomarkers of perinatal depression aligned to the clinically validated PHQ-9 scale, eliminating the need for wearables or additional clinic visits. Developed and validated using data from more than 2,000 women, the underlying AI model classifies concern versus no concern with 93% precision. The app is currently being trialled with the NHS through a partnership with the University of Nottingham and Nottinghamshire Healthcare NHS Foundation Trust, and its research received first prize for Best Research Poster at the Royal College of Obstetricians and Gynaecologists (RCOG) Perinatal Mental Health Conference.

Committed to innovation and data security, Blueskeye holds ISO 27001 certification, complies with the EU AI Act and GDPR, and has an extensive intellectual property portfolio. Its technology is deployed across healthcare, FMCG, social robotics and automotive sectors. In 2022, the company secured £3.4 million in seed funding led by XTX Ventures.